BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic

PHASE4CompletedINTERVENTIONAL
Enrollment

668

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
Covid19MorbidityAbsenteeism
Interventions
BIOLOGICAL

BCG-Denmark

Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.

BIOLOGICAL

Saline

Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.

Trial Locations (2)

1004

Bandim Health Project, Bissau

1929

Manhiça Health Research Centre, Manhiça

All Listed Sponsors
collaborator

Institute of Hygiene and Tropical Medicine, NOVA University, Lisbon, Portugal

UNKNOWN

collaborator

University of Cape Verde, Praia, Cape Verde

UNKNOWN

collaborator

National Institute of Public Health of Cape Verde, Praia, Cape Verde

UNKNOWN

collaborator

Centro de Investigacao em Saude de Manhica

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

Bandim Health Project, Bissau, Guinea-Bissau

UNKNOWN

lead

University of Southern Denmark

OTHER

NCT04641858 - BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic | Biotech Hunter | Biotech Hunter